DS
QNCX icon

David Shaw’s Quince Therapeutics QNCX Stock Holding History

David Shaw’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,588
Closed -$705K – 5462
2022
Q2 		$705K Buy
1,588
+383
+32% +$271K ﹤0.01% 3849
2022
Q1 		$1.49M Buy
1,205
+98
+9% +$133K ﹤0.01% 3581
2021
Q4 		$2.79M Buy
1,107
+1,027
+1,284% +$6.27M ﹤0.01% 3039
2021
Q3 		$1.47M Buy
80
+57
+248% +$907K ﹤0.01% 3293
2021
Q2 		$239K Buy
+23
New +$193K ﹤0.01% 4388
2020
Q4 		– Sell
-65
Closed -$646K – 4120
2020
Q3 		$646K Sell
65
-76
-54% -$691K ﹤0.01% 3096
2020
Q2 		$1.3M Buy
141
+75
+114% +$687K ﹤0.01% 2744
2020
Q1 		$601K Buy
+66
New +$651K ﹤0.01% 3107

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

David Shaw's QNCX Position: Q3 2022 in Review

David Shaw sold out of Quince Therapeutics (QNCX) in Q3 2022, closing a stake of 1,588 shares — an estimated $705K sold.

David Shaw first reported a position in QNCX in Q1 2020 and held it in 8 quarters. The position peaked at $2.79M in Q4 2021. 58 funds tracked by Wall St. Rank hold QNCX as of Q3 2022.

  • David Shaw reported no remaining Quince Therapeutics position as of Q3 2022 after selling out during the quarter.
  • David Shaw sold 1,588 Quince Therapeutics shares in Q3 2022, an estimated $705K.
  • David Shaw first reported a position in Quince Therapeutics in Q1 2020 and held it in 8 quarters.
  • David Shaw's Quince Therapeutics position peaked at $2.79M in Q4 2021.
  • 58 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.